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Oral administration of the combination of L-threonate (threonate) and magnesium (Mg2þ) in the form of
L-Threonic acid Magnesium salt (L-TAMS) can enhance learning and memory in young rats and prevent
memory decline in aging rats and in Alzheimer’s disease model mice. Recent results from a human
clinical trial demonstrate the efﬁcacy of L-TAMS in restoring global cognitive abilities of older adults.
Previously, we reported that neuronal intracellular Mg2þ serves as a critical signaling molecule for
controlling synapse density, a key factor that determines cognitive ability. The elevation of brain Mg2þ by
oral administration of L-TAMS in intact animals plays a signiﬁcant role in mediating the therapeutic
effects of L-TAMS. The current study sought to elucidate the unique role of threonate. We aimed to
understand if threonate acts directly to elevate intraneuronal Mg2þ, and why Mg2þ given without
threonate is ineffective for enhancing learning and memory ability. We discovered that threonate is
naturally present in cerebrospinal ﬂuid (CSF) and oral treatment with L-TAMS elevated CSF threonate. In
cultured hippocampal neurons, threonate treatment directly induced an increase in intracellular Mg2þ
concentration. Functionally, elevating threonate upregulated expression of NR2B-containing NMDAR,
boosted mitochondrial membrane potential (DJm), and increased functional synapse density in neuronal
cultures. These effects are unique to threonate, as other common Mg2þ anions failed to have the same
results. Mechanistically, threonate’s effects were speciﬁcally mediated through glucose transporters
(GLUTs). We also evaluated the effects of threonate in human neural stem cell-derived neurons, and
found it was equally effective at upregulating synapse density. The current study provides an explanation
for why threonate is an essential component of L-TAMS and supports the use of L-TAMS to promote
cognitive abilities in human.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
L-Threonate, (2R,3S)-2,3,4-Trihydroxybutanoate, is a naturally
occurring sugar acid present in the body, with the structure C4H7O5.
It has been found in the periphery in plasma and the aqueous hu-
mor of the eye (Deutsch et al., 1999; Harding et al., 1999). How
threonate is eliminated from the body is not fully understood;
however, so far we know that approximately 10% is excreted in
urine (Lawson et al., 1976; Thompson et al., 1975;Wang et al., 2011).
Recent studies show that threonate might have a physiological
function. In the periphery, threonate has been linked to bone
health. Threonate can prevent bone degradation by inhibitingt, CA 94538, USA.
r Ltd. This is an open access articlosteoclast resorption from bone (He et al., 2005). Threonate also
supports bone formation in two ways. One, it promotes calcium
bioavailability, allowing for rapid absorption of calcium into the
body (Wang et al., 2013). Two, threonate increases bone minerali-
zation by inhibiting DHT-inducible dickkoppf-1 (DKK-1) expres-
sion. DKK-1 is an osteoblast inhibitory factor whose overexpression
can negatively impact bone formation and density (Kwack et al.,
2008, 2010; Monroe et al., 2012).
Our previous work showed that threonate also has effects in the
central nervous system (CNS). Oral treatment with the combination
of threonate and magnesium (Mg2þ) in the form of L-threonic acid
Magnesium salt (L-TAMS) increases synapse density and memory
ability in both aged rats and late stage Alzheimer’s disease (AD)
model mice (Li et al., 2014; Slutsky et al., 2010). A recent study
shows that L-TAMS is also effective at improving cognitive deﬁcits
in humans (Liu et al., 2015).e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ated with synaptic loss (Jack et al., 2015; Ridha et al., 2006; Terry
et al., 1991). In fact, alteration of synaptic efﬁcacy in the hippo-
campus is an initial event in cognitive disorders such as AD (Selkoe,
2002). Considering synapses are the elemental unit of neural
computation, it is not surprising that the both the physical loss of
synapses (reduced structural density) and the loss of function
among the remaining synapses (reduced functional synapse den-
sity) are associated with impaired cognition. Notably, we have
demonstrated that neuronal intracellular Mg2þ concentration
[Mg2þ] is a critical signaling molecule regulating structural and
functional terminal density, with higher intracellular [Mg2þ]
resulting in greater structural and functional terminal density
(Zhou and Liu, 2015).
Our work has shown that not only does neuronal intracellular
Mg2þ promote structural synapse density and plasticity, but it also
controls whether presynaptic terminals are functional or
nonfunctional (Zhou and Liu, 2015). Functional synapses are able to
release neurotransmitter containing vesicles and thus affect the
post-synaptic neuron, while nonfunctional synapses are structur-
ally present but fail to release neurotransmitter and are unable to
signal to the post-synaptic neuron.
Threonate is a critical component of L-TAMS; when animals are
treated with Mg2þ that is not coupled to threonate (ie. an alternate
anion such as chloride is used), there is no signiﬁcant effect on
memory ability (Slutsky et al., 2010). However, threonate treatment
alone, without Mg2þ, also does not affect memory ability, sug-
gesting that there is a synergistic effect between threonate and
Mg2þ (Slutsky et al., 2010).
While L-TAMS has been shown to be effective at improving
cognition, there are still unanswered questions about the unique
role of threonate and why L-TAMS treatment is effective at
improving learning and memory ability but Mg2þ treatment in the
absence of threonate is not. These questions were examined in the
current study. Speciﬁcally, we investigated if there is uptake of
threonate into the CNS following oral treatment with L-TAMS, and
if threonate itself has any effects on hippocampal neurons. Because
threonate and Mg2þ are both required for effects on cognition in an
intact animal, we explored their interaction, focusing on how
threonate affects Mg2þ homeostasis in the neuron, and functional/
structural synapse density. Finally, and perhaps most importantly,
we asked whether threonate is naturally present in the CNS and if it
has any physiological functions.
2. Materials and methods
2.1. Experimental animals
Male Sprague-Dawley rats were purchased from Vital River
Laboratory (Animal Technology Co. Ltd., Beijing, China) and bred in
Tsinghua University’s laboratory animal center. All rats were indi-
vidually housed in a controlled environment, under an inverted
light cycle (light onset at 8:00 p.m. to 8:00 a.m.) and had free access
to food and water. On arrival and before the start of the experi-
ments (see below), rats were fed a commercial pelleted diet
(Shanghai SLAC Laboratory Animal Co. Ltd), containing normal
Mg2þ (0.15%) and tap water ad lib. All procedures on rats were
approved by Tsinghua University Committee on Animal Care.
2.2. Threonate measurement in plasma and CSF
For testing baseline plasma and CSF threonate concentrations, 3
month old rats were fed deionized water without threonate for 1
month. Water was removed for 6 h prior to sample collection as a
washout period. Then, using the previously describe minimumeffective dose of L-TAMS (Neurocentria, Inc., CA, USA) in rats
(604 mg/kg/day) (Slutsky et al., 2010), rats were administered
either L-TAMS (via deionized drinking water) for 1 month or water
only (control). Rat chow for both groups contained basic nutritional
Mg2þ concentration at 0.15%. Prior to blood and CSF collection,
water was removed for 6 h as a washout period.
To determine threonate concentrations in the plasma and ce-
rebrospinal ﬂuid (CSF), rats were anesthetized with Chloral hydrate
(350 mg/kg, i.p.), and then blood and CSF samples were collected
from the orbital sinus and cisterna magna, respectively. Blood
(0.5e1 ml/rat) and CSF (50e100 mL/rat) samples were collected,
centrifuged, and stored at20 C until threonatemeasurement was
performed.
Threonate levels in plasma and CSF were determined by high-
performance liquid chromatography-tandem mass spectrometry
(HPLC-MS/MS, Center of Biomedical Analysis, Tsinghua University)
as described previously (Wang et al., 2006). Brieﬂy, after a simple
protein precipitation with methanol, Plasma and CSF samples were
centrifuged at 14,800 rpm for 15 min, and then the supernatants
were collected for analysis. An Eclipse Plus C18 column
(4.6 100mm, 3.5 mm) (Agilent Technologies, Santa Clara, CA, USA)
was employed to separate the analyte. The mobile phase consisted
of two solvents: 12.5 mM ammonia, 15 mM ammonium acetate in
water (A) and 100% methanol (B). Gradient conditions: 0e2.5 min
90% A/10% B; 2.5e5 min 90e20% A/10e80% B. The ﬂow rate was
0.4 mL/min. The Agilent 6460 triple Quadrupole mass spectrometer,
equipped with Electrospray Ion Source (EIS) was operated under a
negative ionization mode. Multiple reactions monitoring (MRM)
transition of m/z 135.1/ 75.0 was chosen to quantify threonate.
Calibration curves were obtained for the following range of thre-
onate concentrations: 10e1000 nM/L.
2.3. Hippocampal neuron cultures
Hippocampal neurons were prepared from postnatal d1 rats
from Vital River Laboratory and cultured as previously described
(Liu et al., 1999; Liu and Tsien, 1995). Following a previously
described neuronal culture protocol (Kaech and Banker, 2006), and
based on the known insulin/insulin-like growth factor concentra-
tions in rat (Steffens et al., 1988), we added 10 ng/ml insulin (in
addition to insulin in B27) into 0.6 mM extracellular [Mg2þ] culture
medium. 2 days after plating, cytosine arabinoside (ARA-C, Sigma)
was added to a ﬁnal concentration of 2.5 mM to inhibit glial pro-
liferation. Neurons were plated onto Matrigel (BD)-coated
8  8 mm coverslips or 6-well plates (Corning).
2.4. Treatment with threonate and other anions
We used sodium-L-threonate (NaT, Biotium, USA) to study
short-term (4 h) and long-term (2 days) treatment of threonate on
mature hippocampal neurons (14e21 days in vitro: DIV). The
following anions were used in this study: citrate (200 mM), gluco-
nate (1 mM), malate (5 mM) and glycinate (400 mM) (all from
Sigma). The dosage of analogs in culture medium was determined
by their known concentrations in vivo (Hoffmann et al., 1993;
Subramanian et al., 2005). For chemical structures see
Supplemental Fig. 1.
2.5. Intracellular free Mg2þ analysis
Intracellular [Mg2þ] was determined by using Magnesium
Green™ (MgGreen, Invitrogen) as described previously (Fox et al.,
2007; Zhou and Liu, 2015). Brieﬂy, neurons were incubated in
2ml tyrode’s buffer (NaCl, 124mM; KCl, 5 mM; CaCl2, 2 mM;MgCl2,
1 mM; glucose, 30 mM; and HEPES, 25 mM, pH 7.4 with NaOH)
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times, and images were collected using an Olympus IX-70 confocal
microscope with a 60 water lens, at a 4 zoom. As described by
Zhou and Liu (Zhou and Liu, 2015):
h
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Where F(a.u.) is the mean ﬂuorescent density (arbitrary units) in the
branch of interest which was quantiﬁed using Image-Pro Plus
software (IPP, Media Cybernetics, Carlsbad, CA), and Ddiameter is the
meanwidth of the same selected branch in differential interference
contrast (DIC) image.
2.6. Calculation of functional terminal density by FM1-43 imaging
The technique to quantify a functional terminal is detailed in
Zhou and Liu (Zhou and Liu, 2015). Functional terminal density at a
dendritic branch was deﬁned as the number of synaptic terminals
that can undergo synaptic vesicle turnover after physiological
stimulation per unit area of dendritic branch. We used FM-dye
staining to determine the functional status of a synaptic terminal.
Brieﬂy, mature hippocampal neurons (14e21 DIV) were stained
with 10 mM FM1-43 (synaptogreen, Biotium) following physiolog-
ical pattern of stimulus (6 bursts of 5 APs each at 100 Hz with a 10 s
interburst interval) to get image F1, as described by (Slutsky et al.,
2004; Zhou and Liu, 2015). Background was determined by the
image following destaining (480 APs at 2 Hz; F2). DF (DF ¼ F1  F2)
is proportional to the number of vesicles undergoing endocytosis
after physiological stimuli. A terminal is considered to be functional
if it can release at least one vesicle after 30 APs staining stimulation.
Fluorescent images were acquired with an Olympus IX-70
confocal microscope with a 60 water lens (numerical aperture;
NA ¼ 1.2) at a dimension of 78.6  78.6 mm. The density of func-
tional terminal was estimated by using IPP. Each DF image was the
F1 loading image minus the F2 unloading image (DF¼ F1 F2). The
number of FM1-43þ puncta (N) was measured from the corre-
spondingDF image. The length (l), diameter (d), and calculated area
(A ¼ l  d) of each branch was determined from DIC images. The
number of FM1-43þ puncta per mm2 of dendrite (N/A) was calcu-
lated to determine the density of functional terminal in the branch,
and themean density of 30e50 branches was averaged to represent
the functional terminal density in one DF image. We obtained im-
age of DF from loading image F1 and unloading image F2
(DF ¼ F1  F2).
2.7. Measurement of mitochondrial function
Mitochondrial function of hippocampal neurons was observed
microscopically (Olympus IX-70) by using 5,50,6,60-tetrachloro-
1,10,3,30-tetraethylbenzimidazolyl-carbocyanine iodide (JC-1, Invi-
trogen) (Smiley et al., 1991; Szelechowski et al., 2014). The mono-
meric form of JC-1 has an emission maximum at 529 nm. At higher
concentrations or potentials the dye forms red ﬂuorescent J-ag-
gregates with an emission maximum of 590 nm. The ratio of J-
aggregate/J-monomer is used as an estimate of transmembrane
potential (DJm).
Mature neurons were loaded for 20 min at 37 C with 1 mM JC-1
in tyrode’s buffer. After loading, neurons were washed twice with
tyrode’s buffer, and 3e5 images were collected from the coverslip
at 180 magniﬁcation. Each sequential JC-1 monomer (green;
510e575 nm) and JC-1 aggregate (red; >575 nm) image was
collected at the same time. Then we calculated the ratio of ﬂuo-
rescence at >575 nm (red) versus 510e575 nm (green) (Faggregate/
Fmonomer) to represent the DJm of each individual mitochondrion.DJm > 0.26 (Faggregate/Fmonomer) was set as the lower threshold, as
deﬁned previously (see method in (Zhou and Liu, 2015)). The
average DJm of all mitochondrial puncta in 3e5 images represents
the average DJm of a coverslip, and the mean DJm of 5e8 cover-
slips represents the mean DJm of each group. The number of JC-1
aggregate(þ) ﬂuorescent puncta represents the number of mito-
chondrion, since the number of mitochondrion by measuring
number of JC-1 aggregate(þ) ﬂuorescent puncta was the same as
measuring number of Mito-View633(þ) puncta (Zhou and Liu,
2015). DIC images were used to measure the area of each branch.
NMITOwas calculated to represent the level of mitochondrial density
(number of mitochondrion per area of branches). NMITO  DJmwas
generated to show the functional status of mitochondrion.
2.8. Differentiation of human neural stem cells to neurons
Human fetal cortices-derived neural stem cells (hNSC; Angecon,
China) were cultured in hNSC medium (Angecon) according to
guidelines provided by Angecon. hNSCs were maintained in this
medium for 10e14 days, passaged using Accutase (Invitrogen),
washed and replated at a dilution of 1:3 to 1:5.
We used a previously described differentiation protocol to
differentiate hNSCs to neurons (Shi and Jiao, 2012). Brieﬂy, hNSC
cultures were dissociated into single cells with Accutase, and then
plated on polyornithine/laminin (Sigma)-coated 6-well plates at
50,000 cells per cm2 in neural maintenance medium with EGF
(Invitrogen) and FGF2 (PeproTech) at a concentration of 10 ngml1.
Neural maintenance medium consists of a 1:1 mixture of DMEM/
F12 and Neurobasal medium (Invitrogen), 1  N2 (Invitrogen),
1  B27 (Invitrogen), 1 mM L-glutamine, 0.1 mM non-essential
amino acids, 5 mg ml1 insulin, 0.1 mM 2-mercaptoethanol,
25 U ml1 penicillin and 25 mg ml1 streptomycin. After 3e4 days,
when cells reached 95% conﬂuency, culture medium was changed
to a neural induction medium, consisting of neural maintenance
medium, 500 ng ml1 Noggin (R&D Systems) and 10 mM SB431542
(Tocris). Neurons were maintained 10e14 days in this medium;
medium was replaced every day. When neuroepithelial cells
appeared, Dispase (Roche) was used to collect cells. They were
replated in neural maintenance medium with EGF and FGF2 at
20 ng ml1 for 2e4 days, then changed to neural maintenance
medium and cultured for up to 80 days, replacing medium every
other day.
2.9. Immunocytochemistry
Neuronal cultures were washed three times in 0.01 M PBS fol-
lowed by ﬁxation for 20 min in 4% paraformaldehyde at 4 C. The
neuronal culture coverslips were then washed in 1 PBS before
incubation in blocking solution containing 0.1% Triton X-100 and 1%
bovine serum albumin for 30 min at room temperature. Then,
neurons were incubated with mouse anti-PSD-95 (AB2723, Abcam,
1:100), guinea pig anti-MAP2 (188004, Synaptic Systems, 1:300)
and rabbit anti-synaptophysin (MAB5258, Millipore, 1:100) in
blocking solution at 4 C overnight. On the following day, neurons
were rinsed with 1 PBS before 2 h incubation with secondary
antibodies including: donkey anti-mouse IgG-CF 488A 1:100,
donkey anti-guinea pig IgG-CF 555 1:300 and donkey anti-rabbit
IgG-CF 640R 1:200 (Biotium). Finally, neurons were mounted
onto slides with anti-fade ﬂuorescent mounting medium (Vector
Laboratories) and stored at 4 C for 2 days.
2.10. Quantiﬁcation of Synaptophysin and PSD-95
Cultures were imaged with a confocal laser invertedmicroscope
(Olympus IX-70) equipped with a 60 (NA 1.2) objective. Each
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with a serial z projection of 5 images (thickness of 0.8 mm). Then,
the stack of images was compressed to generate a ﬁnal image at the
maximal intensity. Synaptophysin (Syn) staining (red puncta) and
PSD-95 staining (green puncta) were aligned to generate Co-
localized Syn & PSD-95 staining (yellow puncta) images.
The density of Syn, PSD-95, and Co-localized Syn & PSD-
95 þ puncta was estimated by using IPP. We equalized background
levels and separated ﬂuorescent puncta with IPP ﬁlters. 50e60
branches were selected from a MAP2 stained image, the length (l)
and diameter (d) of each branch were measured, and l  d was
calculated to estimate the area (A) of the branch. The number of red,
green, and yellow puncta (N) was measured from the same branch.
N/A was calculated separately for red, green, and yellow puncta,
which represented the density of puncta in the branch. The mean
density of the 50e60 branches was calculated to estimate the
density of Syn, PSD-95, and Co-localized Syn & PSD-95 þ puncta in
one image, and the values from 5 to 7 images were averaged to
determine the mean puncta density in a coverslip.
2.11. Western blot
Samples of threonate-treated and control hippocampal neurons
were solubilized in RIPA buffer (Sigma) containing protease in-
hibitors (Roche) and phosphatase inhibitors (Roche), and then
equal amount of proteins were loaded onto 10% polyacrylamide
gels. Proteins were transferred to PVDFmembranes (Millipore), and
probed with primary antibodies including Synaptophysin (Milli-
pore), RIM1, Rab3a (both from Synaptic System), PSD-95, NR2B, b-
tubulin and b-actin (all from Cell Signaling Technology), followed
by an appropriate HRP-coupled secondary antibody (Cell Signaling
Technology). The signals were detected by ECL detection reagent
(GE Healthcare) and captured on autoradiography ﬁlm (Kodak). For
quantiﬁcation of protein signals, the integrated optical density
(IOD) was measured with IPP, and b-tubulin or b-actin in the same
lane served as a loading control.
2.12. Transfection
Green ﬂuorescent protein (GFP)-expressing NR2B (GFP-NR2B)
(Luo et al., 2002) and mKate2 (Shcheglovitov et al., 2013) plasmids
(mKate2 was used as a transfection control) were co-transfected
into 7 DIV neurons plated on coverslips, using the Ca2þ phos-
phate method. The transfection mediumwas prepared with DMEM
(Gibco) and DNA-Ca2þ-phosphate precipitate was prepared using
Clontech CalPhos Mammalian Transfection Kit (BD Bioscience).
After transfection, on 14 DIV, half of the coverslips were treated
with 150 mM threonate for 2 days before imaging. Images were
collected at a resolution of 512 512with a pixel width of 0.267 mm
using a CCD camera (Andor). A 60 NA 1.20 water-immersion
objective (Olympus) was used. Z-stacks of GFP-NR2B and mKate2
were photographed with 0.5 mm step, and then projected at
maximum in the z direction. For each spine, the ﬂuorescence of
GFP-NR2B and mKate2 was measured in the open-source software
Fiji (ImageJ) and the ratio (FGFP-NR2B/FmKate2) was used to represent
the quantity of expression of NR2B, where FmKate2 was used to
calibrate the efﬁciency of transfection and the local volume of the
spine.
2.13. Statistical analysis
All data are shown as mean ± SEM (standard error of the mean).
Statistical signiﬁcance was determined by two-tailed paired (same
rats)/unpaired Student’s t test, Kolmogorov-Smirnov test, or one-
way/two-way ANOVA, followed by Bonferroni’s post hoc test. Nrepresents total number of rats, and n represents the total number
of separate cultures or coverslips. P < 0.05 was considered statis-
tically signiﬁcant.
3. Results
3.1. Body distribution of threonate and accumulation of threonate
in CSF after oral threonate treatment
Initially, we examined the distribution of threonate in the body.
Similar to previous reports (Wang et al., 2006, 2013), plasma
threonate concentrationwas approximately 20 mM. Interestingly, in
the CSF, threonate concentration was approximately 100 mM, about
5-fold higher than in the periphery (p < 0.001, Fig. 1A). Then, we
studied the effects of oral dosing of L-TAMS (604 mg/kg/day) on the
plasma and CSF concentrations of threonate. Since it takes >2
weeks of L-TAMS treatment to have a noticeable effect on CSF Mg2þ
concentration and memory function, we monitored the concen-
tration of threonate in plasma and CSF after 1 month treatment
(Slutsky et al., 2010) (see experimental paradigm, Fig. 1). Following
oral L-TAMS treatment for 1 month, and 6 h washout, threonate
concentration did not change in plasma (Fig. 1B), indicating there
was no accumulation in the periphery and that it could be quickly
cleared (within 6 h). In contrast, threonate concentration increased
signiﬁcantly in the CSF by 54% (p¼ 0.01, Fig.1C). These data indicate
that with L-TAMS treatment, threonate accumulated in the CNS
compartment, leading to sustained elevation of brain threonate,
while in the peripheral compartment threonate did not
accumulate.
3.2. Raising extracellular threonate concentration promotes
elevation of intracellular magnesium concentration
Our recent studies indicate that synaptic changes after raising
extracellular [Mg2þ] are due to an increase of intracellular [Mg2þ]
(Zhou and Liu, 2015). Therefore, we asked whether treatment with
threonate would elevate intracellular [Mg2þ] in cultured rat hip-
pocampal neurons. Since we were interested in the effects of
threonate on neuronal function, and hypothesized that any effects
are mediated through changes in intracellular magnesium con-
centration, we tested the effects of threonate over a range of
extracellular [Mg2þ], including 0.6, 0.8 and 1.2 mM. Since 0.8 mM
extracellular [Mg2þ] in brain is considered physiological and there
are reports of age-dependent and pathophysiological-related re-
ductions (such as in Alzheimer’s Disease) in CSF magnesium of
20e30%, 0.6 mM extracellular [Mg2þ] represented this observed
lower Mg2þ concentration (Andrasi et al., 2005; Cilliler et al., 2007).
Neurons were cultured for two weeks at 0.6, 0.8, or 1.2 mM
extracellular [Mg2þ]. Intracellular [Mg2þ] was quantiﬁed by MgGrn
ﬂuorescent dye (see methods). Intracellular [Mg2þ] was signiﬁ-
cantly higher at 0.8 and 1.2mM extracellular [Mg2þ] than at 0.6mM
extracellular [Mg2þ] (F2,19 ¼ 39.10, p < 0.0001; Fig. 2A, B). These
observations are consistent with our previous ﬁnding that extra-
cellular [Mg2þ] affected intracellular [Mg2þ] with a bell-shaped
relationship (Zhou and Liu, 2015). 2 day treatment with threonate
(0e200 mM) induced an increase of intracellular [Mg2þ] in a
dosage-dependent manner at various extracellular [Mg2þ]
(0.6 mM Mg, F4,26 ¼ 19.03, p < 0.0001; 0.8 mM Mg, F4,27 ¼ 12.88,
p < 0.0001; 1.2 mM Mg, F4,25 ¼ 17.78, p < 0.0001; Fig. 2A, B), up to
150 mM threonate (Fig. 2B). Using the threonate concentration that
induced the largest change in intracellular [Mg2þ] (150 mM), we
performed a time course analysis of the effects of threonate on
intracellular [Mg2þ] (Fig. 2C, D). Threonate effects were maximal at
2 h and this increase persisted for the entire course of the experi-
ment (F5,26 ¼ 10.83, p < 0.0001; Fig. 2D). Intracellular [Mg2þ]
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Fig. 1. Elevation of brain threonate by L-TAMS. (A) Threonate concentrations (mM) in plasma and CSF were determined in 4 month old rats (N ¼ 16) fed with normal chow and water.
Each circle or square represents an individual rat. (BeC) Schematic of L-TAMS treatment paradigm. 3 month old rats were treated with normal water for one month, then blood and
CSF were collected after a 6 h washout period (“Before”), which constituted the control samples. Then rats were treated for one month with L-TAMS and blood and CSF samples
were collected after a 6 h washout period (“After”). Threonate concentrations (mM) in the plasma (B; N ¼ 12) and CSF (C; N ¼ 9) were determined before and after 1 month
treatment with L-TAMS. The concentration in plasma and CSF for each timepoint is shown for each rat. The average of each group at each timepoint is shown in the histogram
behind the individual rat data. Unpaired t test (A), paired t test (B, C); *p < 0.05, ***p < 0.001.
Fig. 2. Raising extracellular threonate concentration promotes elevation of intracellular Mg2þ concentration ([Mg2þ]i). (A) Left panel) Representative MgGreen ﬂuorescent images
(pseudo-colored) of dendrites with extracellular Mg2þ concentration ([Mg2þ]o) of 0.6 mM and 0.8 mM. Right panel) High magniﬁcation images of MgGreen (pseudo-colored images)
and DIC (gray), showing individual branches with varying concentrations of [Mg2þ]o (0.6 or 0.8 or 1.2 mM Mg; long-term, LT ¼ 2 weeks) and threonate (0e200 mM; 2 days). (B)
[Mg2þ]i was calculated as normalized F(a.u) by dividing each branch’s MgGreen F(a.u) by its mean diameter (measured from DIC images). The resulting averages for each [Mg2þ]o and
threonate concentration are displayed. One-way ANOVA compared differences in [Mg2þ]i at different [Mg2þ]o (0.6 mM Mg, n ¼ 7; 0.8 mM Mg, n ¼ 8; 1.2 mM Mg, n ¼ 7 coverslips).
For each [Mg2þ]o, one-way ANOVA compared neuronal [Mg2þ]i in response to increasing threonate concentrations (n ¼ 5e6 per concentration) relative to 0 mm threonate
(control); þþþp < 0.001; *p < 0.05; **p < 0.01; ***p < 0.001. (C) Representative MgGreen (pseudo-colored) and DIC (gray) ﬂuorescent images of individual branches after time
course (0e36 h) of threonate treatment (150 mM). (D) Time course line graph of average neuronal [Mg2þ]i (n ¼ 4e6); one-way ANOVA and Bonferroni’s post hoc test, **p < 0.01,
***p < 0.001 versus control (h 0).
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to short-term threonate treatment (data not shown).
3.3. Raising extracellular threonate concentration increases
synaptic density and upregulates NR2B-containing NMDAR
expression
Our previous study shows that intracellular [Mg2þ] plays an
important role in controlling structural and functional synapse
density. Since threonate treatment elevated intracellular [Mg2þ], it
is of interest to determine if elevation of threonate can also increase
synaptic density and plasticity.
Presynaptic terminal density was quantiﬁed by the density of
Synaptophysin (Syn) puncta (number per mm2) (Lowenstein et al.,
1995; Tarsa and Goda, 2002) and postsynaptic glutamatergic syn-
apse density was quantiﬁed by the density of PSD-95 puncta (Hunt
et al., 1996). Overall synapse density was determined by the co-
localization of Syn and PSD-95 expression (Glantz et al., 2007;
Siew et al., 2004). Threonate treatment signiﬁcantly upregulated
the number of Syn puncta, PSD-95 puncta (Syn, F3,16 ¼ 4.318,
p ¼ 0.0207; PSD-95, F3,16 ¼ 6.315, p ¼ 0.005; Fig. 3A, B: left panel),
and Syn/PSD-95 co-localized puncta (Co-localization, F3,16 ¼ 5.653,
p ¼ 0.0078; Fig. 3A, B: middle panel). We also checked whether
threonate changed the percentage of excitatory synapses, which is
deﬁned as the number of Syn/PSD-95 co-localized puncta divided
by the number of Syn puncta. With threonate treatment, the per-
centage of excitatory synapses did not signiﬁcantly change (Fig. 3A,
B: right panel), suggesting that threonate treatment did not change
the balance of the neuronal network.
We used Western blot to verify the increase of pre- and post-
synaptic proteins in hippocampal neuronal cultures following
threonate treatment. After 2 days of threonate treatment, Syn and
PSD-95 expression were signiﬁcantly increased (Fig. 3C). We also
checked the expression of two presynaptic proteins critical for the
functional status of presynaptic terminals, Rab3a and RIM1 (Zhou
and Liu, 2015). Similar to Syn and PSD-95, Rab3a and RIM1
expression were signiﬁcantly increased following threonate treat-
ment (Syn: F3,44 ¼ 7.38, p ¼ 0.0004, n ¼ 12; PSD-95: F3,36 ¼ 3.350,
p ¼ 0.0295, n ¼ 10; Rab3a: F3,56 ¼ 12.45, p < 0.0001, n ¼ 15; RIM1:
F3,24 ¼ 5.946, p ¼ 0.0035, n ¼ 7; Fig. 3C).
NR2B-containing NMDAR plays an important role in controlling
synaptic plasticity (Le Roux et al., 2007). Upregulation of its
expression is sufﬁcient to enhance learning and memory ability
(Tang et al., 1999). Elevation of extracellular [Mg2þ] can selectively
increase synaptic NR2B-containing NMDAR (Slutsky et al., 2004,
2010). We checked whether threonate treatment can also affect
NR2B. Threonate treatment signiﬁcantly upregulated NR2B-
containing NMDAR in hippocampal neurons (F3,17 ¼ 7.493,
p ¼ 0.0021; Fig. 4A).
To assess whether threonate treatment increased synaptic NR2B
expression, we transfected neurons with GFP-labeled NR2B (GFP-
NR2B), using mKate2 transfection as an internal control. FGFP-NR2B/
FmKate2 in each individual spine represents the expression of NR2B.
Threonate treatment directly elevated expression of synaptic NR2B.
On average, FGFP-NR2B/FmKate2 was 30% higher in threonate group
(Kolmogorov-Smirnov test, p < 0.0001; Fig. 4B, C).
Collectively, threonate-treated neurons exhibited higher struc-
tural synaptic density, and higher expression of proteins critical for
synaptic plasticity.
3.4. Threonate increases functional presynaptic terminal density
and enhances mitochondrial function
Having studied the effects of threonate on structural synaptic
density, we next investigated the effects of threonate onpresynaptic terminal function. We used FM dye to evaluate the
terminals’ ability to undergo activity dependent vesicular turnover
(Liu and Tsien, 1995; Ryan et al., 1993; Slutsky et al., 2004). Vesic-
ular endocytosis triggered by stimulation results in FM dye uptake.
Terminals labeled by FM as a result of physiological pattern of
stimulus are deﬁned as functional (for detailed experimental pro-
tocol see (Zhou and Liu, 2015)). Mature hippocampal neuronal
cultures (14e21 DIV) with varying concentrations of extracellular
[Mg2þ] (0.6, 0.8, 1.2 mM) were treated with threonate (0e150 mM)
for 2 days. The FM dye staining results are shown in Fig. 5A.
Threonate treatment induced a similar pattern of change in func-
tional terminal density as it did in intracellular [Mg2þ] (Fig. 2B). The
number of functional terminals was signiﬁcantly higher at 0.8 and
1.2 mM than 0.6 mM extracellular [Mg2þ] (F2,14¼14.27, p¼ 0.0004;
Fig. 5A, B), and increased following threonate treatment in a dose-
dependent manner under all extracellular [Mg2þ] conditions tested
(0.6 mM Mg: F3,21 ¼ 15.15, p < 0.0001; 0.8 mM Mg: F3,16 ¼ 8.946,
p ¼ 0.001; 1.2 mM Mg: F3,16 ¼ 3.088, p ¼ 0.057; Fig. 5A, B).
Next, we evaluated the effects of threonate treatment on the
release probability (Pr) of individual synapses and the total synaptic
input per unit area of dendrite to determine whether the increase
of functional synapse density affects the homeostasis of synaptic
input to the dendrite (Liu and Tsien, 1995). We used a 30 APs at
0.5 Hz stimulation protocol to determine the Pr of a single terminal,
described previously (Slutsky et al., 2004). Interestingly, while
threonate treatment lead to an ~27% increase in terminal density
(N), it also induced the reduction of Pr by ~20%, such that total
synapse inputs (S) to a unit area of dendrite remained constant
(Fig. 5 C, D), indicating that the homeostasis of functional synapse
density and individual synapse Pr remains constant during threo-
nate treatment.
Our recent data show that the local energy supply critically
determines the functionality of terminals. Intracellular [Mg2þ]
plays a pivotal role in controlling mitochondrial efﬁciency, which in
turn determines the local energy supply and functional terminal
density. If threonate can elevate intracellular [Mg2þ], it might
improve the functional status of mitochondria, leading to an in-
crease in functional terminal density. To assess mitochondrial
function, we examined their density (NMITO) and membrane po-
tential (DJm) in the network, two important parameters for
quantiﬁcation of mitochondria function (NMITO  DJm) (Buckman
and Reynolds, 2001; Nicholls and Ward, 2000). We used the ratio
of J-aggregate to J-monomer form of JC-1 to estimate DJm (see
methods) (Smiley et al., 1991; Szelechowski et al., 2014). Addition of
threonate for 2 days to hippocampal neurons signiﬁcantly
increased NMITO by 9.2%, enhanced DJm by 49.6%, and improved
(NMITO  DJm) by 63% compared to controls (Unpaired t test,
p < 0.01; Fig. 5E, F), suggesting that threonate treatment enhanced
neuronal mitochondrial function.
3.5. Comparison of effects of various anions on intracellular
magnesium and functional synaptic density
The above data suggests that threonate has a direct effect in
promoting an increase of intracellular [Mg2þ]. For elevation of
hippocampal neuron [Mg2þ], it was of interest to see whether other
major anions have a similar effect. By comparing the molecular
structure of compounds that have or do not have this effect, one
might be able to ascertain the membrane channel/carrier involved
in elevation of intracellular [Mg2þ].
For comparison, we selected malate, citrate, and gluconate for
their structural similarity to threonate as sugar acids, and glycinate
because it is purported to promote cation absorption in the pe-
riphery (Hertrampf and Olivares, 2004). These molecules were
tested under 0.6 mM extracellular [Mg2þ] conditions, and
Fig. 3. Enhancement of synaptic density by threonate. Hippocampal neuronal cultures were treated with threonate for 2 days. (A) Representative ﬂuorescent images of synaptic
terminal marker synaptophysin (Syn) and spine marker PSD-95 of controls (n ¼ 5) and threonate-treated hippocampal neurons (n ¼ 4e6) at varying threonate concentrations
(0e150 mM); n means number of coverslips, 5e7 images for one coverslip, and 50e60 branches for one image. Scale bar represents 2 mm. (B) Quantiﬁcation of Syn and PSD-95-
immunostained puncta. Left panel) the absolute number of Syn and PSD-95; Middle panel) amount of Syn & PSD-95 co-localized; Right panel) the percentage (%) of excitatory
synapses (% of excitatory synapses was calculated as the density of co-localized Syn and PSD-95 puncta divided by the density of total Syn puncta). One-way ANOVA compared
number of puncta in threonate-treated neurons to controls; *p < 0.05; **p < 0.01. (C) Western blot and quantitative analysis of synaptic proteins Syn, PSD-95, Rab3a and RIM1
expression in hippocampal neuronal cultures treated with threonate (0e150 mM). b-tubulin was used as a loading control. Data is represented as fold change relative to control
(0 mM threonate). One-way ANOVA and Bonferroni’s post hoc test; *p < 0.05, **p < 0.01, ***p < 0.001; n means number of separate cultures.
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(F5,19 ¼ 3.455, p ¼ 0.0218; Fig. 6A, B).
Next, we compared these molecules in their ability to increase
functional synapse density in hippocampal neurons. After 2 days of
treatment, only threonate was able to signiﬁcantly increase func-
tional terminal density (F5,25¼10.99, p< 0.0001; Fig. 6C, D). Citrate,
gluconate, malate, and glycinate treatments had no signiﬁcant ef-
fects. The fact that only threonate resulted in a change in intra-
cellular [Mg2þ] and functional terminal density gave insight into
the underlying mechanistic pathway by which threonate enhances
synaptic changes.3.6. GLUTs necessary for threonate-induced synaptic changes and
increase of functional synapse density
Since only threonate was effective at increasing intracellular[Mg2þ] and functional synaptic density, we focused on its transport
mechanisms. Elevated intracellular [Mg2þ] might be due to
increased Mg2þ inﬂux, reduced Mg2þ efﬂux, and/or release of Mg2þ
from organelles (Shindo et al., 2010). We tested whether the
elevation of intracellular Mg2þ by threonate depends on Mg2þ
inﬂux. Since Mg2þ inﬂux is driven by a concentration gradient
between extracellular and intracellular Mg2þ, a signiﬁcant reduc-
tion of extracellular Mg2þ will diminish the gradient, preventing
Mg2þ inﬂux. If the threonate effects disappear under low extra-
cellular [Mg2þ] conditions (0.1 mM), then the effects of threonate
are likely mediated through Mg2þ inﬂux.
In line with previous experiments, threonate treatment for 4 h,
at 0.6 mM extracellular [Mg2þ], induced a signiﬁcant ~27% increase
of intracellular [Mg2þ] (p < 0.001). When extracellular [Mg2þ] was
reduced to 0.1 mM for 4 h, intracellular [Mg2þ] did not decline
(Fig. 7A, B), but, addition of threonate no longer induced elevation
Fig. 4. Upregulation of NR2B-containing NMDAR by threonate. (A) Western blot and quantitative analysis for NR2B-containing NMDAR protein in hippocampal neurons. b-actin was
used as a loading control. One-way ANOVA and Bonferroni’s post hoc test; *p < 0.05; **p < 0.01. (B) Representative images with GFP-NR2B (pseudo-color) and mKate2 (gray) of
hippocampal neurons following treatment with threonate (150 mM) for 2 days. Scale bar represents 5 mm. (C) Expression of NR2B in each dendritic spine was calculated from images
represented in B (197 spines for control, and 206 spines for threonate-treated neurons on 3 coverslips for each condition). The ratio of FGFP-NR2B/FmKate2 in each individual spine
represents the quantify of NR2B expression; F means ﬂuorescence intensity. The distribution of expression of NR2B in spines is shown in the left panel, and mean expression of
NR2B is shown in the histogram in the right panel. FGFP-NR2B/FmKate2 values were normalized to control group. Kolmogorov-Smirnov test, p < 0.0001.
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[Mg2þ] to 0.1 mM for 4 h did not reduce functional terminal density
(Fig. 7Cc, D) relative to control extracellular [Mg2þ] (Fig. 7Ca, D).
However, this condition prevented threonate from increasing
functional terminal density (Fig. 7Cd, D).
These results indicate that threonate elevated intracellular
[Mg2þ] of hippocampal neurons most likely by increasing net ﬂux
of Mg2þ into the neuron, resulting in the increase of functional
terminal density; although, the possibility that threonate promotes
functional synapse density independently of Mg2þ cannot be ruled
out.
Our focus was to identify the transporter that underlies
threonate-mediated Mg2þ inﬂux. There are no known transporters
for threonate, but because threonate is a derivative of ascorbic acid/
DHA, we investigated if threonate acted through ascorbic acid and/
or DHA transporters. Ascorbic acid is transported by glucose
transporters (GLUTs) (Rumsey et al., 1997) and sodium-dependent
vitamin C transporter 2 (SVCT2) (Harrison and May 2009; Savini
et al., 2008), which are highly expressed in the CNS (McEwen and
Reagan, 2004; Tsukaguchi et al., 1999).
To speciﬁcally target GLUTs and SVCT2, we utilized cytochalasin
B (CB) and Phloretin, because of their ability to inhibit GLUTs (Yu
et al., 1993) and SVCT2 (Gess et al., 2010), respectively. While
short-term incubation (4 h) of hippocampal neuronal cultures with
threonate increased intracellular [Mg2þ] (29.6%, p < 0.001), this
threonate-mediated increase was prevented by the addition of CB.
CB alone did not alter intracellular [Mg2þ] relative to control
(Fig. 7E, F). In contrast, treatment with Phloretin did not affect the
ability of threonate to signiﬁcantly increase intracellular [Mg2þ]
(23.5%, p < 0.001) (Fig. 7E, F). These results suggest an involvement
of GLUTs, but not SVCT2, in the modulation of intracellular [Mg2þ]
by threonate which can lead to augmentation of functional termi-
nal density.
We then checked whether blocking GLUTs or SVCT2 by CB or
Phloretin would affect the ability of threonate to elevate functionalterminal density of hippocampal neurons. CB treatment alone did
not affect the density of functional terminals relative to control;
however, in the presence of CB, threonate treatment was unable to
elevate functional terminal density (Fig. 7Gd, H), similar to the ef-
fects of CB on threonate-mediated increase of intracellular [Mg2þ].
Addition of Phloretin signiﬁcantly decreased functional terminal
density (10.5%, p < 0.01) in hippocampal cultures, and was unable
to block threonate-mediated increase of functional terminal den-
sity relative to control (20.4%) (Fig. 7Gf, H). Altogether, we conclude
that GLUTs mediate threonate-induced increases in neuronal
intracellular [Mg2þ] and functional synapse density.
3.7. Threonate upregulated expression level of Syn and PSD-95 in
human neural stem cell-derived neurons
To help understand the potential ramiﬁcations of the present
study in human, we examined the effects of threonate on synaptic
changes in human stem cell-derived neurons. In a separate study,
we found plasma threonate concentrations were similar between
human and rat; but human CSF threonate concentrations
(100e300 mM), were much higher than those in rat (internal
observation). Threonate function may vary between rodent and
human due to species differences in ascorbate synthesis and
plasma and CSF concentrations (Burns, 1957; Harrison and May
2009; Horowitz et al., 1952; Jackel et al., 1950; Miele and Fillenz,
1996; Pauling, 1970; Reiber et al., 1993; Schenk et al., 1982). To
test this, human neuronal cultures were derived from human
neural stem cells (hNSC) (Shi and Jiao, 2012). We evaluated the
effects of threonate on human neurons using Western blot to check
the expression of pre- and postsynaptic proteins, which is supposed
to be proportional to the number of synapses (Glantz et al., 2007).
Fig. 8A shows the experimental protocol used for deriving
neurons from hNSC. In this cell line, structural and functional
synapses are present at day 45 following induction of differentia-
tion (Shi and Jiao, 2012). We observed glutamatergic synapses
Fig. 5. Threonate increases functional presynaptic terminal density and enhances mitochondrial function. (A) Representative ﬂuorescent FM1-43 (pseudo-colored) and DIC (gray)
images of control (0 mM threonate) and threonate-treated (50e150 mM) neurons. Each FMþ puncta is a functional synaptic terminal. (B) Functional terminal density was calculated
from images represented in A (see methods, n ¼ 5e7 coverslips). One-way ANOVA compared functional terminal density in 0.6 mMMg (n ¼ 7), 0.8 mMMg (n ¼ 5), and 1.2 mMMg
(n ¼ 5) to 0 mM threonate. For each [Mg2þ]o (0.6, 0.8 or 1.2 mM), threonate-treated neurons (50e150 mM; n ¼ 5e7) were compared to controls (0 mM), separately, using one-way
ANOVA and Bonferroni’s post hoc test. þp < 0.05, þþþp < 0.001; **p < 0.01, ***p < 0.001. (C) Representative ﬂuorescent FM1-43 (pseudo-color) and mKate2 (gray) images of
hippocampal neurons following treatment with threonate (150 mM) for 2 days (mKate2 was used to calculate the total area of dendrites). Puncta number per mm2 of dendrite was
calculated to determine the density of terminals (N). The intensity of FMþ puncta is proportional to the probability of transmitter release (Pr). Synaptic strength (S) to a unit area of
dendrite is calculated as N  Pr. (D) N, Pr, and S of terminals were calculated from images represented in A (n ¼ 3 coverslips, each coverslip contained 9 areas of interest). Student t
tests for N, Pr, and S compared threonate-treated versus control conditions, **p < 0.01, ***p < 0.001. (E) Representative ﬂuorescent images of hippocampal neuronal cultures dyed
with JC-1 to determine mitochondrial function following treatment with threonate (150 mM) for 2 days. Mitochondrial transmembrane potential (DJm) was measured by ratio of JC-
1 aggregate (red) and monomer (green). Dashed boxes (m1 and m2) are high magniﬁcations of regions marked in the low magniﬁcation images. Scale bar represents 2 mm. (F)
Histogram of average mitochondrial density (NMITO), DJm, and functional status (NMITO  DJm) (Control, 0.6 mM Mg, n ¼ 8 coverslips; threonate, n ¼ 5 coverslips). Unpaired t test
compared parameters in threonate-treated neurons to controls; **p < 0.01.
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gray) at day 80, via ﬂuorescent co-localization of presynaptic pro-
tein Syn (red puncta) and postsynaptic protein PSD-95 (green
puncta) (Fig. 8Ac-g), and treated the human neurons with threo-
nate at day 90. Similar to our ﬁndings in cultured rat hippocampal
neurons, threonate treatment signiﬁcantly increased Syn and PSD-
95 expression in a dose-dependent manner (Syn, F4,67 ¼ 4.499,
p ¼ 0.0028; PSD-95, F4,44 ¼ 4.221, p ¼ 0.0056; Fig. 8B, C). Inter-
estingly, compared to the rat dose response curve, in human neu-
rons, the threonate dose response curve was shifted toward a
higher concentration, such that even at 400 mM, a concentrationhigher than human physiological concentration, the effects of
threonate continued to increase. This shift seems to be matched
with the higher concentration of threonate in human CSF.
4. Discussion
Threonate is an endogenous small molecule shown to have a
possible physiological function in the periphery - supporting bone
health. However, until now, there have been no reports of the
presence of or a physiological role for threonate in the CNS. In the
current study, we showed for ﬁrst time that threonate is present in
Fig. 6. Comparison of effects of various anions on [Mg2þ]i and functional synaptic density. (A) Representative MgGreen (pseudo-colored) and DIC (gray) ﬂuorescent images of
individual branches after 2 day treatment with threonate or threonate analogs at 0.6 mM [Mg2þ]o (control). (B) Histogram of average [Mg2þ]i calculated from the MgGreen and DIC
images represented in A. All compound-treated neurons (n ¼ 4 coverslips) were compared to controls (n ¼ 5 coverslips). One-way ANOVA and Bonferroni’s post hoc test; *p < 0.05.
(C) Representative ﬂuorescent FM1-43 (pseudo-colored) and DIC (gray) images of hippocampal neuronal cultures following treatment with threonate or threonate analogs for 2
days at 0.6 mM [Mg2þ]o (control). (D) Histogram of functional terminal density calculated from images represented in C (n ¼ 5e6 coverslips). All compound-treated neurons were
compared to controls. One-way ANOVA and Bonferroni’s post hoc test; **p < 0.01.
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approximate 5-fold higher concentration than in the periphery. We
identiﬁed threonate as a unique molecule that can efﬁciently
regulate structural and functional synaptic density in the CNS. Here
we show that threonate treatment of hippocampal neuronal cul-
tures increased mitochondrial function, proteins critical for syn-
aptic plasticity, and structural and functional synapse density, in a
dose-dependent manner. Importantly, we also identiﬁed the
likely signaling mechanism by which threonate affects functional
synapse density. We show that threonate elevates neuronal intra-
cellular [Mg2þ], which acts as a “second messenger” for threonate
in regulating synapse density (Zhou and Liu, 2015).
We have carried out experiments to decipher the possible
mechanism underlying the elevation of neuronal intracellular
[Mg2þ] by threonate, which could be due to increased Mg2þ inﬂux
or decreased Mg2þ efﬂux. We observed that when we dropped
extracellular [Mg2þ] to 0.1 mM in an attempt to reduce the driving
force for Mg2þ inﬂux, threonate treatment no longer elevated
intracellular [Mg2þ]. These results are most compatible with the
interpretation that threonate promotes Mg2þ inﬂux.
We conducted several experiments to identify the possible
channel responsible for threonate-mediated Mg2þ inﬂux into
neurons. The candidates we considered were channels that have
high potential to transport threonate, including GLUTs and SVCT2,
based on threonate’s structure and related chemical precursors.
Threonate is formed by the spontaneous conversion of the ascorbic
acid oxidation product dehydroascorbic acid (DHA) into oxalic acid
and threonic acid (Kallner et al., 1985; Thornalley, 1998). GLUTs
have speciﬁcity for the threonate precursor DHA and is also known
to transport monosaccharides and other small carbon compoundsvia passive facilitated transport, whereas SVCT2 has speciﬁcity for
ascorbic acid (Augustin, 2010; Rumsey et al., 1999). Blocking GLUTs,
but not SVCT2, suppressed both threonate-mediated Mg2þ inﬂux
and increase of functional synaptic density. Although the CB ex-
periments suggest that GLUTs are responsible for threonate-
mediated inﬂux of Mg2þ into neurons, since the speciﬁcity of CB
to GLUTs cannot be completely conﬁrmed, additional experiments,
such as siRNA knock-down, are required before we can conclusively
conclude that it is GLUTs that mediate the action of threonate on
intracellular Mg2þ concentration. Nevertheless, given the chemical
structure similarity between DHA and threonate, we speculate that
GLUTs facilitate threonate transport into the cell while co-
transporting Mg2þ.
Because the drug we used to block GLUTs is not speciﬁc for a
particular GLUT, we do not know which of the GLUTs expressed in
the brain (GLUTs 1e4, 6, 8, 10, 13) are capable of threonate-
mediated transport of Mg2þ into neurons. Although, among the
brain expressed GLUTs, GluTs 1 and 3 are known to transport DHA,
suggesting that they might also be responsible for threonate
transport (Rumsey et al., 1997). GluT3, but not GluT1, is highly
constitutively expressed on hippocampal neurons as the primary
mediator of neuronal glucose uptake (Leino et al., 1997; Maher
et al., 1991; Nagamatsu et al., 1992; Vannucci et al., 1997). There-
fore, threonate-induced transport of Mg2þ into hippocampal neu-
rons likely occurred primarily through GluT3 in our experiments.
Interestingly, GluT1 is highly expressed on endothelial cells of the
blood brain barrier, important for glucose uptake into the brain
(Koranyi et al., 1991; Simpson et al., 2001; Yeh et al., 2008).
Therefore, GluT1 may be responsible for the observed threonate-
mediated transport of Mg2þ into the brain (Slutsky et al., 2010).
Fig. 7. Glucose transporters (GLUTs) are essential for threonate-induced synaptic changes and increase of functional synapse density. (A) Representative MgGreen (pseudo-colored)
and DIC (gray) ﬂuorescent images of individual branches after 4 h treatment with or without threonate (150 mM) in neuronal cultures at 0.6 mM or 0.1 mM [Mg2þ]o. (B) Histogram of
average [Mg2þ]i calculated from the MgGreen and DIC images represented in A. Two-way ANOVA compared [Mg2þ]i at 0.6 and 0.1 mM [Mg2þ]o with threonate to without threonate,
with Bonferroni’s post hoc test (n ¼ 4e10 coverslips). (C) Representative ﬂuorescent FM1-43 (pseudo-colored) and DIC (gray) images of hippocampal neuronal cultures following
treatment with threonate (150 mM, 4 h) or control (0 mM threonate) in 0.6 mM [Mg2þ]o (control) or in 0.1 mM [Mg2þ]o. (D) Histogram of functional terminal density calculated from
images represented in C (n ¼ 6 coverslips). Two-way ANOVA compared functional terminal density at 0.6 and 0.1 mM [Mg2þ]o with threonate to without threonate, with Bon-
ferroni’s post hoc test. (EeH) Hippocampal cultures were incubated with threonate, cytochalasin B (CB; GLUTs inhibitor, 10 mM), and/or Phloretin (SVCT2 inhibitor, 150 mM) for 4 h.
(E) Representative MgGreen (pseudo-colored) and DIC (gray) ﬂuorescent images of individual branches following 4 h treatment with threonate (150 mM) or control (0 mM
threonate) with or without CB or Phloretin. (F) [Mg2þ]i was calculated as normalized F(a.u) by dividing each branch’s MgGreen F(a.u) by its mean diameter (measured from DIC
images), from images represented in E. Two-way ANOVA was used to compare [Mg2þ]i in different conditions, Bonferroni’s post-hoc test (n ¼ 4e17 coverslips). (G) Representative
ﬂuorescent FM1-43 (pseudo-colored) and DIC (gray) images of hippocampal neuronal cultures after threonate (150 mM) or control (0 mM threonate) treatment with CB or Phloretin.
(H) Histogram of functional terminal density calculated from images represented in G. Two-way ANOVA compared effect of threonate, CB or Phloretin on functional terminal density
to controls, and effect of threonate on functional terminal density in the presence of CB or Phloretin, respectively, with Bonferroni’s post-hoc test (n ¼ 6e15 coverslips), **p < 0.01,
***p < 0.001.
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brain function. Indeed, the decline of cognitive function during
aging is strongly correlated with the degree of synapse loss
(Morrison and Baxter, 2012). Identifying the endogenous molecule
that regulates synapse density will likely be of broad signiﬁcance.
So far, only a handful of endogenous molecules have been shown to
have a role in upregulating synapse density. For example, estrogen
can efﬁciently increase synapse density in hippocampal neurons
(Mukai et al., 2010). Acetyl-L-carnitine (ACL), a derivative of the
constitutively expressed fatty acid transporter L-carnitine, can
potentially promote hippocampal dendritic spine density (Kocsis
et al., 2014). The current study shows that threonate might be an
important constitutively present molecule in the CSF required for
maintaining high synapse density.
Translationally, a threonate or Mg2þ compound might be useful
to increase synapse density and promote learning and memory.
Surprisingly, in our previous animal experiments, we found that
treatment with either threonate or Mg2þ but without the other was
ineffective (Slutsky et al., 2010). Only treatment with thecombination of threonate and Mg2þ as a single compound can
elevate memory ability. While oral treatment with threonate and
Mg2þ (in the form of L-TAMS) can efﬁciently increase synapse
density and memory ability in both aged rats and late stage AD
model mice (Li et al., 2014; Slutsky et al., 2010), threonate treat-
ment without Mg2þ (in the form of NaT) and Mg2þ treatment
without threonate (in the form of Mg2þ-chloride, -citrate, -glyci-
nate, and egluconate) fails to increase short- or long-termmemory
ability (Slutsky et al., 2010).
If threonate is effective in increasing intraneuronal Mg2þ and
synapse density in cultured hippocampal neurons, it is curious why
it does not have an effect in the intact animal. One possible
explanation is that threonate might not be able to promote Mg2þ
inﬂux into neurons without a simultaneous increase of extracel-
lular brain Mg2þ supply. This is because Mg2þ as a signaling
molecule is unique in that the majority of Mg2þ is stored inside the
cell and there is a relatively very small amount of Mg2þ in the
extracellular space. Therefore, a large inﬂux of Mg2þ can lead to a
signiﬁcant reduction of extracellular Mg2þ, thereby reducing the
Fig. 8. Elevating threonate increased expression of Syn and PSD-95 in human neurons. (A) (a) Schematic of protocol for differentiation of human neural stem cells (hNSC) into
neurons and subsequent threonate treatment. (b) Neurospheres at optimal size for passaging after proliferation. (ceg) Confocal microscopy images of immunoﬂuorescent staining
for hNSC-derived neurons. (c) Images of dendrites (MAP2, gray) showing localization of foci of the excitatory synapse. Physical synapses (arrows in g) were identiﬁed by juxta-
position of pre- (Syn; e, red) and postsynaptic (PSD-95; f, green) proteins on dendritic branches (d, gray). (BeC) Representative Western blot (B) and quantiﬁed histogram (C) of Syn
(n ¼ 9e18) and PSD-95 (n ¼ 6e13) in control and threonate-treated hNSC-derived neurons. b-tubulin was used as a loading control. Data are presented as fold change relative to
control. One-way ANOVA and Bonferroni’s post hoc test; *p < 0.05; **p < 0.01.
Q. Sun et al. / Neuropharmacology 108 (2016) 426e439 437driving force of Mg2þ, preventing further inﬂux. This phenomenon
can be observed with insulin treatment. Insulin promotes Mg2þ
inﬂux into the cell, signiﬁcantly reducing extracellular Mg2þ. For
example, plasma Mg2þ levels initially decrease signiﬁcantly
following an insulin injection, but can be prevented when insulin is
injected with Mg2þ supplementation, such as from a meal (Paolisso
et al., 1986). Since the amount of total extracellular brain Mg2þ is
low (Ramadan et al., 1989), threonate treatment without concur-
rent Mg2þ treatment, like with insulin treatment, could quickly
reduce CSF Mg2þ, resulting in a reduction of the driving force for all
Mg2þ channels, limiting the amount of Mg2þ inﬂux that threonate
can promote. This might explain why threonate treatment alone
does not work in vivo, whereas in culture, where the extracellular
[Mg2þ] is essentially clamped, threonate treatment effectively in-
creases intracellular [Mg2þ].
Similar to the effects of increasing CSF threonate without
increasing Mg2þ, increasing CSF Mg2þ without increasing CSF
threonate will also not be effective. One cannot limitlessly elevate
extracellular brain Mg2þ in order to elevate intracellular [Mg2þ], as
the relationship between extracellular and intracellular [Mg2þ],and the relationship of extracellular [Mg2þ] and synapse density
are bell-shaped. As shown in Fig. 2 and Fig. 5, when the extracel-
lular [Mg2þ] is increased beyond 0.8 mM, intracellular [Mg2þ] and
synapse density decreased.
The greatest increase in vitro of intracellular [Mg2þ] and func-
tional synapse density occurred with the concurrent increase of
threonate and extracellular [Mg2þ] (Figs. 2B and 5A, B). In vivo,
threonate and Mg2þ oral treatment (L-TAMS) increased brain
threonate by approximately 50% (Fig. 1C) and CSF Mg2þ by
approximately 15%, leading to an increase of synapse density by as
much as 67% (Slutsky et al., 2010). The current study provides more
mechanistic insight into the therapeutic potential of L-TAMS for
cognitive impairment. A recent double-blinded placebo-controlled
clinical study showed promise for L-TAMS in treating cognitive
impairment in humans (Liu et al., 2015).Acknowledgments
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